Dapsone for the treatment of acne vulgaris: do the risks outweigh the benefits?

References

• Sago J, Hall RP, III. Dapsone. Dermatol Ther 2002;15:340–351.
   Google Scholar
• Wozel VG. Innovative use of dapsone. Dermatol Clin 2010;28:599–610.
   PubMed Web of Science ®Google Scholar
• Ghaoui N, Hanna E, Abbas O, et al. Update on the use of dapsone in dermatology. Int J Dermatol 2020;59:787–795.
   PubMed Web of Science ®Google Scholar
• Piskin S, Uzunali E. A review of the use of adapalene for the treatment of acne vulgaris. Ther Clin Risk Manag 2007;3:621.
   PubMedGoogle Scholar
• Nast A, Dréno B, Bettoli V, et al. European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version. J Eur Acad Dermatol Venereol 2016;30:1261–1268.
   PubMed Web of Science ®Google Scholar
• Ozturk Z, Tatliparmak A. Leprosy treatment during pregnancy and breastfeeding: a case report and brief review of literature. Dermatol Ther 2017;30:e12414.
   Google Scholar
• Wolf R, Matz H, Orion E, et al. Dapsone. Dermatoloji dergisi 2002;8(1):2–20.
   Google Scholar
• Molinelli E, Paolinelli M, Campanati A, et al. Metabolic, pharmacokinetic, and toxicological issues surrounding dapsone. Expert Opin Drug Metab Toxicol 2019;15:367–379.
   PubMed Web of Science ®Google Scholar
• Searle T, Al‐Niaimi F, Ali FR. Dapsone for acne: still in use after half a century! J Cosmet Dermatol 2021;20:2036–2039.
   PubMedGoogle Scholar
• Kanoh S, Tanabe T, Rubin BK. Dapsone inhibits IL-8 secretion from human bronchial epithelial cells stimulated with lipopolysaccharide and resolves airway inflammation in the ferret. Chest 2011;140:980–990.
   PubMed Web of Science ®Google Scholar
• Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res 2014;306:103–124.
   PubMed Web of Science ®Google Scholar
• Tan J. Dapsone 5% gel: a new option in topical therapy for acne. Skin Therapy Lett 2012;17:1–3.
   PubMedGoogle Scholar
• Karadag AS, Parish LC, Lambert WC. Isotretinoin in retrospect. Clin Dermatol 2017;35:335–339.
   PubMedGoogle Scholar
• Thiboutot DM, Willmer J, Sharata H, et al. Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. Clin Pharmacokinet 2007;46:697–712.
   PubMed Web of Science ®Google Scholar
• Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol 2007;56:439-e1.
   Google Scholar
• Pickert A, Raimer S. An evaluation of dapsone gel 5% in the treatment of acne vulgaris. Expert Opin Pharmacother 2009;10:1515–1521.
   PubMed Web of Science ®Google Scholar
• Lucky AW, Maloney JM, Roberts J, et al. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. J Drugs Dermatol 2007;6:981–987.
   PubMedGoogle Scholar
• Taylor SC, Cook-Bolden FE, McMichael A, et al. Efficacy, safety, and tolerability of topical dapsone gel, 7.5% for treatment of acne vulgaris by Fitzpatrick skin phototype. J Drugs Dermatol 2018;17:160–167.
   PubMed Web of Science ®Google Scholar
• Jarratt MT, Jones TM, Chang-Lin JE, et al. Safety and pharmacokinetics of once-daily dapsone gel, 7.5% in patients with moderate acne vulgaris. J Drugs Dermatol 2016;15:1250–1259.
   PubMedGoogle Scholar
• Al-Salama ZT, Deeks ED. Dapsone 7.5% gel: a review in acne vulgaris. Am J Clin Dermatol 2017;18:139–145.
   PubMed Web of Science ®Google Scholar
• Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016;74:945–973.
   PubMed Web of Science ®Google Scholar
• Ross CM. The treatment of acne vulgaris with dapsone. Br J Dermatol 1961;73:367–370.
   PubMed Web of Science ®Google Scholar
• Prendiville JS, Logan RA, Russell‐Jones R. A comparison of dapsone with 13-cis retinoic acid in the treatment of nodular cystic acne. Clin Exp Dermatol 1988;13:67–71.
   PubMed Web of Science ®Google Scholar
• Daye M, Temiz SA. A case of nodular cystic acne treated with systemic dapsone. Jarem 2020;10:103–106.
   Google Scholar
• Didona D, Paolino G, Donati P, Muscardin LM. Resolution of nodulocystic acne with oral dapsone. Dermatol Ther 2017;30:
   Google Scholar
• Wakabayashi M, Fujii N, Fujimoto N, Tanaka T. Usefulness of dapsone for the treatment of Asian severe acne. J Dermatol 2013;40:502–504.
   PubMedGoogle Scholar
• Tan BB, Lear JT, Smith AG. Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone. Clin Exp Dermatol 1997;22:26–27.
   PubMed Web of Science ®Google Scholar
• Al-Kathiri L, Al-Najjar T. Severe nodulocystic acne not responding to isotretinoin therapy successfully treated with oral dapsone. Oman Med J 2018;33:433.
   PubMedGoogle Scholar
• Legal K, Misery L. Isotretinoin-induced acne fulminans without systemic symptoms treated successfully with oral dapsone. Acta Derm Venerol 2020;100:1–2.
   Google Scholar
• Hornsten P, Keisu M, Wilholm B. The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988. Arch Dermatol 1990; 126:919–922.
   PubMed Web of Science ®Google Scholar
• Coleman M. Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention. Toxicology 2001; 162:53–60.
   PubMed Web of Science ®Google Scholar
• St. Claire K, Kaul S, Caldito EG, et al. Dapsone kaynaklı agranülositoz-semptomlar, mevcut kan izleme protokolünden daha güvenilir bir şekilde uyarı verebilir. İngiliz Dermatoloji Dergisi. 2020;184(5):962–963.
   Google Scholar
• Pamba A, Richardson ND, Carter N, et al. Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. Blood 2012;120:4123–4133.
   PubMedGoogle Scholar
• Zhu KJ, He FT, Jin N, et al. Complete atrioventricular block associated with dapsone therapy: a rare complication of dapsone-induced hypersensitivity syndrome. J Clin Pharm Ther 2009;34:489–492.
   PubMedGoogle Scholar
• Hoogeveen RM, van der Bom T, de Boer HH, et al. A lethal case of the dapsone hypersensitivity syndrome involving the myocardium. Neth J Med 2016;74:89–92.
   PubMed Web of Science ®Google Scholar
• Kim HK, Jeong NR, Park JH, Jang HJ. Dapson Nedenli Eozinofilik Pnömoni Olgusu. Amerikan Toraks Derneği. 2018;35:6634–6634.
   Google Scholar
• Ezhilarasan D. Dapsone-induced hepatic complications: it’s time to think beyond methemoglobinemia. Drug Chem Toxicol 2021;44:330–333.
   PubMed Web of Science ®Google Scholar
• Ghishan FK. The sulfone syndrome complicated by pancreatitis and pleural effusion in an adolescent receiving dapsone for treatment of acne vulgaris. J Ped Gastroenterol Nutr 1998;26:103–105.
   PubMedGoogle Scholar
• Alves-Rodrigues EN, Ribeiro LC, Silva MD, et al. Dapsone syndrome with acute renal failure during leprosy treatment: case report. Braz J Infect Dis 2005;9:84–86.
   PubMedGoogle Scholar
• McCarty M. How clinically relevant is dapsone-related peripheral neuropathy? An overview of available data with emphasis on clinical recognition. J Clin Aesthetic Dermatol 2010;3:19.
   PubMedGoogle Scholar
• Tempark T, Satapornpong P, Rerknimitr P, et al. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population. Pharmacogenet Genom 2017;27:429–437.
   PubMed Web of Science ®Google Scholar
• Bommakanti J, Namoju R, Jabeen T, et al. A case of dapsone hypersensitivity syndrome in an Indian leprosy patient: retrospective screening reveals the genetic connection with HLA-B*13:01. Dermatol Ther 2020;33:e13825.
   PubMedGoogle Scholar
• Vinod KV, Arun K, Dutta TK. Dapsone hypersensitivity syndrome: a rare life threatening complication of dapsone therapy. J Pharmacol Pharmacother 2013;4:158.
   PubMedGoogle Scholar
• Zhang FR, Liu H, Irwanto A, et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. N Engl J Med 2013;369:1620–1628.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Agarwalla A. Dapsone hypersensitivity syndrome: a clinico‐epidemiological review. J Dermatol 2005;32:883–889.
   PubMed Web of Science ®Google Scholar
• Kang KS, Kim HI, Kim OH, et al. Clinical outcomes of adverse cardiovascular events in patients with acute dapsone poisoning. Clin Exp Emerg Med 2016;3:41.
   PubMedGoogle Scholar
• Todd P, Samaratunga IR, Pembroke A. Screening for glucose-6-phosphate dehydrogenase deficiency prior to dapsone therapy. Clin Exp Dermatol 1994;19:217–218.
   PubMed Web of Science ®Google Scholar
• Webster GF. Is topical dapsone safe in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients? J Drugs Dermatol 2010;9:532–536.
   PubMed Web of Science ®Google Scholar
• Frayling IM, Addison GM, Chattergee K, Meakin G. Methaemoglobinaemia in children treated with prilocaine-lignocaine cream. BMJ 1990;301:153.
   PubMedGoogle Scholar